Clinical trial
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast…
NCT00005581 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Other · Unknown status
Key facts
| NCT number | NCT00005581 |
|---|---|
| Title | Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer |
| Official title | Epirubicin Plus Paclitaxel Versus Cyclophosphamide, Epirubicin and 5-Fluorouracil as Adjuvant Treatment of Node Positive Breast Cancer Patients: A Controlled Randomized Phase III Study |
| Lead sponsor | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | cyclophosphamide, epirubicin hydrochloride, fluorouracil, paclitaxel |
| Enrollment | 1,000 |
| Start date | Jun 1, 2000 |
| First posted | May 20, 2004 |
| Last update posted | Dec 18, 2013 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: